A Discacciati1, N Orsini2, A Wolk3. 1. Units of Nutritional Epidemiology; Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. Electronic address: andrea.discacciati@ki.se. 2. Units of Nutritional Epidemiology; Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. 3. Units of Nutritional Epidemiology.
Abstract
BACKGROUND: Existing epidemiological evidence is controversial regarding the possible associations between coffee consumption and risk of prostate cancer (PCa) by aggressiveness of the disease. MATERIALS AND METHODS: We conducted a random-effects dose-response meta-analysis to assess the relationships between coffee consumption and nonaggressive, aggressive and fatal PCa risk. Studies were identified by a search of Medline and Embase databases to 15 July 2013. We carried out separate analyses by grade (Gleason score: low-grade, high-grade) and stage (TNM staging system: localized, advanced) of the tumors. Nonaggressive tumors were defined as low-grade or localized, while aggressive tumors were defined as high-grade or advanced. RESULTS: Eight studies (three case-control and five cohort) were included in this meta-analysis. Gleason 7 tumors were classified as high-grade in one study, while in another study, Gleason 7(4 + 3) tumors were classified as high-grade and Gleason 7(3 + 4) as low-grade. In the remaining four studies, Gleason 7 tumors were excluded from the analyses or analyzed separately. The pooled relative risk (RR) for a consumption increment of 3 cups/day was 0.97 [95% confidence interval (CI) 0.92-1.03] for low-grade PCa (n = 6), 0.97 (95% CI 0.94-0.99) for localized PCa (n = 6), 0.89 (95% CI 0.78-1.00) for high-grade PCa (n = 6), 0.95 (95% CI 0.85-1.06) for advanced PCa (n = 6) and 0.89 (95% CI 0.82-0.97) for fatal PCa (n = 4). No evidence of publication bias was observed. Heterogeneity was absent or marginal (I(2) range = 0-26%), with the only exception of the analysis on advanced PCa, where moderate heterogeneity was observed (I(2) = 60%). When restricting the analyses only to those studies that defined high-grade tumors as Gleason 8-10, the inverse association became slightly stronger [RR: 0.84 (95% CI 0.72-0.98); n = 4]. CONCLUSIONS: Results from this dose-response meta-analysis suggest that coffee consumption may be inversely associated with the risk of fatal PCa. No clear evidence of an association with PCa incidence was observed.
BACKGROUND: Existing epidemiological evidence is controversial regarding the possible associations between coffee consumption and risk of prostate cancer (PCa) by aggressiveness of the disease. MATERIALS AND METHODS: We conducted a random-effects dose-response meta-analysis to assess the relationships between coffee consumption and nonaggressive, aggressive and fatal PCa risk. Studies were identified by a search of Medline and Embase databases to 15 July 2013. We carried out separate analyses by grade (Gleason score: low-grade, high-grade) and stage (TNM staging system: localized, advanced) of the tumors. Nonaggressive tumors were defined as low-grade or localized, while aggressive tumors were defined as high-grade or advanced. RESULTS: Eight studies (three case-control and five cohort) were included in this meta-analysis. Gleason 7 tumors were classified as high-grade in one study, while in another study, Gleason 7(4 + 3) tumors were classified as high-grade and Gleason 7(3 + 4) as low-grade. In the remaining four studies, Gleason 7 tumors were excluded from the analyses or analyzed separately. The pooled relative risk (RR) for a consumption increment of 3 cups/day was 0.97 [95% confidence interval (CI) 0.92-1.03] for low-grade PCa (n = 6), 0.97 (95% CI 0.94-0.99) for localized PCa (n = 6), 0.89 (95% CI 0.78-1.00) for high-grade PCa (n = 6), 0.95 (95% CI 0.85-1.06) for advanced PCa (n = 6) and 0.89 (95% CI 0.82-0.97) for fatal PCa (n = 4). No evidence of publication bias was observed. Heterogeneity was absent or marginal (I(2) range = 0-26%), with the only exception of the analysis on advanced PCa, where moderate heterogeneity was observed (I(2) = 60%). When restricting the analyses only to those studies that defined high-grade tumors as Gleason 8-10, the inverse association became slightly stronger [RR: 0.84 (95% CI 0.72-0.98); n = 4]. CONCLUSIONS: Results from this dose-response meta-analysis suggest that coffee consumption may be inversely associated with the risk of fatal PCa. No clear evidence of an association with PCa incidence was observed.
Entities:
Keywords:
coffee; dose–response meta-analysis; epidemiology; prostate cancer
Authors: Aditya Bardia; Elizabeth A Platz; Srinivasan Yegnasubramanian; Angelo M De Marzo; William G Nelson Journal: Curr Opin Pharmacol Date: 2009-07-01 Impact factor: 5.547
Authors: Nicole M Wedick; Aoife M Brennan; Qi Sun; Frank B Hu; Christos S Mantzoros; Rob M van Dam Journal: Nutr J Date: 2011-09-13 Impact factor: 3.271
Authors: Erikka Loftfield; Meredith S Shiels; Barry I Graubard; Hormuzd A Katki; Anil K Chaturvedi; Britton Trabert; Ligia A Pinto; Troy J Kemp; Fatma M Shebl; Susan T Mayne; Nicolas Wentzensen; Mark P Purdue; Allan Hildesheim; Rashmi Sinha; Neal D Freedman Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-05-21 Impact factor: 4.254
Authors: Sam F Peisch; Erin L Van Blarigan; June M Chan; Meir J Stampfer; Stacey A Kenfield Journal: World J Urol Date: 2016-08-12 Impact factor: 4.226
Authors: Crystal S Langlais; June M Chan; Stacey A Kenfield; Janet E Cowan; Rebecca E Graff; Jeanette M Broering; Peter Carroll; Erin L Van Blarigan Journal: Cancer Causes Control Date: 2021-04-09 Impact factor: 2.532
Authors: Mia Hashibe; Carlotta Galeone; Saundra S Buys; Lisa Gren; Paolo Boffetta; Zuo-Feng Zhang; Carlo La Vecchia Journal: Br J Cancer Date: 2015-08-20 Impact factor: 7.640